Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
2018 · Cancer Discovery · 563 citations
https://doi.org/10.1158/2159-8290.cd-18-0774
P
Prajwal Boddu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
90
Papers
2.6K
Citations
26
h-index
39
i10-index
Prajwal Boddu is an academic researcher from Yale Cancer Center. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Chronic Myeloid Leukemia Treatments & Myeloproliferative Neoplasms: Diagnosis and Treatment. The author has an h-index of 26, co-authored 77 publications.
Papers by this author
worksHypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
2018 · Leukemia · 174 citations
https://doi.org/10.1038/s41375-018-0070-8
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
2020 · The Lancet Haematology · 86 citations
https://doi.org/10.1016/s2352-3026(20)30205-2
Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report
2017 · Hematology/Oncology and Stem Cell Therapy · 5 citations
https://doi.org/10.1016/j.hemonc.2017.07.004
Time to response and survival in hypomethylating agent-treated acute myeloid leukemia
2017 · Leukemia & lymphoma/Leukemia and lymphoma · 3 citations
https://doi.org/10.1080/10428194.2017.1365857
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat